Join Indica Labs for May Webinar
Indica Labs: Learn about Indica Labs’ ability to deliver AI-driven CDx
Advancing Precision Medicine Through Pathology and AI-Powered CDx with Indica Labs
Date: 5 May 2026
Time: 8:00 PDT | 11:00 EDT | 16:00 BST
Location: Webinar
Summary
Learning Objectives
- Learn about Indica Labs’ initiatives and strategy for developing AI-powered CDx products in digital pathology
- Gain insight into Indica Labs’ strategic partnership with Leica Biosystems
- Discover how Indica Labs can take AI-based early proof-of–concept studies all the way through the development lifecycle to become a regulatory approved CDx
- Find out about deployment options in the CE-IVDR HALO AP® platform
- Understand the pathway to regulatory approval for CDx co-developed with Indica Labs and options for additional strategic partnerships
HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. WBS-MAR-000022v1
Presenters
Steven Hashagen
CEO and Founder
Indica Labs
Steven Hashagen is the founder and CEO of Indica Labs, a leading digital pathology software and AI company. Prior to forming Indica Labs in 2011, Steven held software engineering, software architect, and product management roles at Aperio Technologies. Through this combined experience Steven has been a pioneer in the digital pathology field for over 20 years.
Peter Caie, PhD
Sr. Director, Precision Medicine
Indica Labs
Peter Caie worked for 9 years as a Senior Scientist at AstraZeneca before completing his PhD from the University of Edinburgh in Cancer Pathology. He went on to run the Quantitative and Digital Pathology (QUAD) Lab at the University of St Andrews where his research focused on artificial intelligence, cancer prognosis and diagnosis in the field of digital and molecular pathology. Currently, Dr. Caie is a Senior Director at Indica Labs where he manages the development of commercial AI products, including CDx assays, designed for deployment in both the clinical and life science fields.
Doug Bowman (Moderator)
VP Precision Medicine
Indica Labs
Doug is responsible for Indica Labs’ Precision Medicine group that partners with pharma companies to bring new AI-powered companion diagnostics to market. His team leads the commercial development of clinical AI solutions that deploy in HALO AP® and span laboratory operations to clinical research and diagnostic use cases. His Pharma Services team, with deep experience in quantitative image analysis services, supports customers’ pre-clinical and clinical biomarker assays. Prior to Indica Labs, he spent 12+ years at Takeda Pharmaceuticals where he led the tissue-based imaging capabilities to support early discovery, translational, and clinical programs. Doug has a BSE in biomedical and electrical engineering from Duke University.
SOURCE: Indica Labs
